Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX Cash-to-Debt is 0.02 as of Jun. 2026, which is 99% below its 10-year median of 3.88. The stock has 4 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 96.63% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Imagion Biosystems's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Imagion Biosystemscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Imagion Biosystems's Cash-to-Debt or its related term are showing as below:
ASX:IBX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 3.88 Max: No Debt
Current: 0.02
During the past 9 years, Imagion Biosystems's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 3.88.
ASX:IBX's Cash-to-Debt is ranked worse than 96.63% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.98
vs ASX:IBX: 0.02
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Imagion Biosystems Cash-to-Debt Related Terms
Imagion Biosystems Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:IBX vs TMO, DHR, NTRA: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (ASX:IBX) has a Cash-to-Debt of 0.02 as of Jun. 2026. This is 99% below median its historical median of 3.88. Over the past decade, Imagion Biosystems' Cash-to-Debt has ranged from 0.02 to 10,000.00. According to the industry distribution chart, Imagion Biosystems ranks #201 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 96.6%.
Is Imagion Biosystems' Cash-to-Debt too high?
Imagion Biosystems' current Cash-to-Debt of 0.02 is 99% below median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 10,000.00. The Medical Diagnostics & Research industry median Cash-to-Debt is 0.98. Imagion Biosystems' value of 0.02 is 98% below this industry median. Based on the distribution chart, Imagion Biosystems ranks #201 out of 208 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #201 out of 208 companies for Cash-to-Debt. This places Imagion Biosystems in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Imagion Biosystems' value of 0.02 is 98% below this benchmark. Historically, Imagion Biosystems' own Cash-to-Debt has ranged from 0.02 to 10,000.00 over the past decade. While the company's 10-year median is 3.88 vs. the industry median of 0.98, Imagion Biosystems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imagion Biosystems's current Cash-to-Debt of 0.02 is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current Cash-to-Debt is 0.02, which is 99% below median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 99.3% below its estimated fair value. The current Cash-to-Debt is 0.02, which is 99% below median its 10-year median of 3.88 and 98% below the Medical Diagnostics & Research industry median of 0.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current Cash-to-Debt is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
